Extensive Line of Anti-Human Protein Antibodies Available
By LabMedica International staff writers Posted on 24 Sep 2014 |
Image: A line of antibodies to human blood proteins offers high quality and flexibility in testing for a wide range of blood proteins (Photo courtesy of The Binding Site).
A line of antibodies to human blood proteins offers the in vitro diagnostics and life sciences sectors high quality and flexibility in testing for a wide range of blood proteins.
The Binding Site, Inc. (San Diego, CA, USA), a leader in manufacturing of primary antibodies and in discovery, development, manufacture, marketing, and sales of novel immunodiagnostic assays, now offers a comprehensive line of anti-human blood protein antibodies for the improvement of patient care. The availability of this extensive line will benefit the needs and efforts of clinical and life science researchers, medical laboratory professionals, and in vitro diagnostic (IVD) manufacturers alike. By utilization of innovative and patented manufacturing techniques, which yield highly specific antibodies, all in the Anti-Human Protein Antibodies line display the highest degrees of purity, shelf life stability, and lot-to-lot consistency.
The scope of antibodies available includes those against human acute-phase reactants, coagulation proteins, complement, immunoglobulins, and other blood proteins (i.e., albumin, prealbumin, transferrin, etc.).
All antibodies are available in an unconjugated format which may be conjugated to Biotin, Fluorescein-Isothiocyanate (FITC), Horseradish Peroxidase (HRP), Rhodamine, and others. Plus, a number of these antibodies are available from Binding Site already pre-conjugated to HRP, FITC, or both. These Anti-Human Protein Antibodies are offered in a convenient, operator-oriented standard packaging size of 1.0 mL, with customer distinct and bulk packaging configurations also being available.
Related Links:
The Binding Site
The Binding Site, Inc. (San Diego, CA, USA), a leader in manufacturing of primary antibodies and in discovery, development, manufacture, marketing, and sales of novel immunodiagnostic assays, now offers a comprehensive line of anti-human blood protein antibodies for the improvement of patient care. The availability of this extensive line will benefit the needs and efforts of clinical and life science researchers, medical laboratory professionals, and in vitro diagnostic (IVD) manufacturers alike. By utilization of innovative and patented manufacturing techniques, which yield highly specific antibodies, all in the Anti-Human Protein Antibodies line display the highest degrees of purity, shelf life stability, and lot-to-lot consistency.
The scope of antibodies available includes those against human acute-phase reactants, coagulation proteins, complement, immunoglobulins, and other blood proteins (i.e., albumin, prealbumin, transferrin, etc.).
All antibodies are available in an unconjugated format which may be conjugated to Biotin, Fluorescein-Isothiocyanate (FITC), Horseradish Peroxidase (HRP), Rhodamine, and others. Plus, a number of these antibodies are available from Binding Site already pre-conjugated to HRP, FITC, or both. These Anti-Human Protein Antibodies are offered in a convenient, operator-oriented standard packaging size of 1.0 mL, with customer distinct and bulk packaging configurations also being available.
Related Links:
The Binding Site
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans